Driving the future of advanced molecular imaging
At EANM 2017, Philips features its latest solutions and technologies that are driving the future of advanced molecular imaging, including:

· Vereos Digital PET/CT – Featuring Philips proprietary Digital Photon Counting (DPC) technology, Vereos offers improved detectability and characterization of small lesions [1]. The system provides uncompromised detectability and quantification at half the PET dose [2]. Vereos also provides lesion detectability in one-tenth of the time [3].

· Ingenuity TF PET/CT – Ingenuity TF PET/CT leverages Philips' Astonish TF technology for enhanced image contrast, resolution, and quality. It also features Philips' proprietary xPand5 quantification tools to assist in measuring and monitoring disease progression. These technologies are combined with advanced CT features, such as iPatient, iDose⁴ and metal artifact reduction for implants (O-MAR), to drive confidence and consistency through personalized patient centric workflow.
· SPECT solutions – CardioMD IV and BodyMD [4] – Cost-efficient cardiac and general purpose SPECT solutions to maximize the return on investment.
· IntelliSpace Portal 9.0 – The latest edition of Philips' comprehensive, advanced visualization and analysis platform offers quantitative tumor tracking and treatment response tools with a streamlined workflow for follow‐up and analysis in oncology cases. IntelliSpace Portal 9.0 provides enterprise‐wide access to a comprehensive suite of Molecular Imaging processing and review applications for general Nuclear Medicine, SPECT, SPECT/CT and PET/CT.

Driving conversation on innovation
This year, Philips hosts a number of talks and presentations in a live forum format at its booth at EANM. In addition, Philips' academic partners present 10 scientific presentations and posters demonstrating the value that Philips' digital PET/CT system is bringing to molecular imaging—advancing knowledge and application using features such as lesion detection and quantitative imaging.

For more information on Philips' molecular imaging solutions, and to learn more about the company's presence at EANM, visit booth 402, www.philips.com/eanm and follow the conversation on @PhilipsLiveFrom.

[1] Nguyen NC, Image Quality and Diagnostic Performance of a Digital PET Prototype in Patients with Oncologic Diseases: Initial Experience and Comparison with Analog PET, J Nucl Med 2015; 56:1378–1385.
[2] Liu X et al, Impact of FDG Dose Reduction on Lesion Quantification in Dynamic PET: A Simulation Study Based on Clinical Trial Data, SNMMI 2016.

Molecular Imaging Homepage